Potential anti-obesogenic properties of non-digestible carbohydrates: specific focus on resistant dextrin
Hobden, M. R., Guérin-Deremaux, L., Rowland, I., Gibson, G. R. Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1017/S0029665115000087 Abstract/SummaryAlterations in the composition and metabolic activity of the gut microbiota appear to contribute to the development of obesity and associated metabolic diseases. However, the extent of this relationship remains unknown. Modulating the gut microbiota with non-digestible carbohydrates (NDC) may exert anti-obesogenic effects through various metabolic pathways including changes to appetite regulation, glucose and lipid metabolism and inflammation. The NDC vary in physicochemical structure and this may govern their physical properties and fermentation by specific gut bacterial populations. Much research in this area has focused on established prebiotics, especially fructans (i.e. inulin and fructo-oligosaccharides); however, there is increasing interest in the metabolic effects of other NDC, such as resistant dextrin. Data presented in this review provide evidence from mechanistic and intervention studies that certain fermentable NDC, including resistant dextrin, are able to modulate the gut microbiota and may alter metabolic process associated with obesity, including appetite regulation, energy and lipid metabolism and inflammation. To confirm these effects and elucidate the responsible mechanisms, further well-controlled human intervention studies are required to investigate the impact of NDC on the composition and function of the gut microbiota and at the same time determine concomitant effects on host metabolism and physiology.
1. Ng M, Fleming T, Robinson M et al. (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet 384, 766–781.
2. Dixon JB (2010) The effect of obesity on health outcomes. Mol Cell Endocrinol 316, 104–108.
3. Kivimaki M, Jokela M, Hamer M et al. (2011) Examining overweight and obesity as risk factors for common mental disorders using fat mass and obesity-associated (fto) genotype-instrumented analysis: the Ehitehall II Study, 1985–2004. Am J Epidemiol 173, 421–429.
4. Department of Health (2011) Healthy lives, healthy people: a call to action on obesity in England.
5. Swinburn B & Egger G (2002) Preventive strategies against weight gain and obesity. Obes Rev 3, 289–301.
6. Kovacs EM & Mela DJ (2006) Metabolically active func- tional food ingredients for weight control. Obes Rev 7, 59–78.
7. Jeukendrup AE & Randell R (2011) Fat burners: nutrition supplements that increase fat metabolism. Obes Rev 12, 841–851.
8. Bellisle F, Blundell J, Dye L et al. (1998) Functional food science and behaviour and psychological functions. Br J Nutr 80, S173–S193.
9. Dye L & Blundell J (2002) Functional foods: psychological and behavioural functions. Br J Nutr 88, S187–S211.
10. Rogers PJ (1995) Food, mood and appetite. Nutr Res Rev 8, 243–269.
11. Nicholson JK, Holmes E, Kinross J et al. (2012) Host-gut microbiota metabolic interactions. Science 336, 1262–1267.
12. Tremaroli V & Backhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature
489, 242–249.
13. Qin J, Li R, Raes J et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65.
14. Roberfroid M, Gibson GR, Hoyles L et al. (2010) Prebiotic effects: metabolic and health benefits. Br J Nutr 104, S1–S63.
15. Cebra JJ (1999) Influences of microbiota on intestinal im- mune system development. Am J Clin Nutr 69, 1046s– 1051s.
16. Molina V, Medici M, Taranto M et al. (2009) Lactobacillus reuteri crl 1098 prevents side effects produced by a nu- tritional vitamin b12 deficiency. J Appl Microbiol 106, 467–473.
17. Cooke G, Behan J & Costello M (2006) Newly identified vitamin k-producing bacteria isolated from the neonatal faecal flora. Microb Ecol Health Dis 18, 133–138.
18. Strozzi GP & Mogna L (2008) Quantification of folic acid in human feces after administration of bifidobacterium pro- biotic strains. J Clin Gastroenterol 42, S179–S184.
19. Abrams SA, Griffin IJ, Hawthorne KM et al. (2005) A combination of prebiotic short- and long-chain inulin- type fructans enhances calcium absorption and bone miner- alization in young adolescents. Am J Clin Nutr 82, 471–476.
20. Sayin SI, Wahlström A, Felin J et al. (2013) Gut micro- biota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17, 225–235.
21. Björkholm B, Bok CM, Lundin A et al. (2009) Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4, e6958.
22. Bergman EN (1990) Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 70, 567–590.
23. Stoddart LA, Smith NJ & Milligan G (2008) International union of pharmacology. Lxxi. Free fatty acid receptors ffa1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60, 405–417.
24. Karaki S, Tazoe H, Hayashi H et al. (2008) Expression of the short-chain fatty acid receptor, gpr43, in the human colon. J Mol Histol 39, 135–142.
25. Tazoe H, Otomo Y, Karaki S et al. (2009) Expression of short-chain fatty acid receptor gpr41 in the human colon. Biomed Res 30, 149–156.
26. Psichas A, Sleeth ML, Murphy KG et al. (2014) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes (Lond) (Epublication ahead of print version).
27. Tolhurst G, Heffron H, Lam YS et al. (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the g-protein-coupled receptor FFAR2. Diabetes 61, 364–371.
28. Lin HV, Frassetto A, Kowalik EJ Jr et al. (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-inde- pendent mechanisms. PLoS ONE 7, e35240.
29. Xiong Y, Miyamoto N, Shibata K et al. (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the g protein-coupled receptor gpr41. Proc Natl Acad Sci USA 101, 1045–1050.
30. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. (2014) The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 5, 3611.
31. De Vadder F, Kovatcheva-Datchary P, Goncalves D et al. (2014) Microbiota-generated metabolites promote metabolic benefits via gut–brain neural circuits. Cell 156, 84–96.
32. Mayer EA (2011) Gut feelings: the emerging biology of gut–brain communication. Nat Rev Neurosci 12, 453– 466.
33. Gao Z, Yin J, Zhang J et al. (2009) Butyrate improves in- sulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517.
34. Yamashita H, Fujisawa K, Ito E et al. (2007) Improvement of obesity and glucose tolerance by acetate in type 2 dia- betic otsuka long-evans tokushima fatty (oletf) rats. Biosci Biotechnol Biochem 71, 1236–1243.
35. Zydowo MM, Smolenski RT & Swierczynski J (1993) Acetate-induced changes of adenine nucleotide levels in rat liver. Metabolism 42, 644–648.
36. Cani PD, Knauf C, Iglesias MA et al. (2006) Improvement of glucose tolerance and hepatic insulin sensitivity by oligo- fructose requires a functional glucagon-like peptide 1 recep- tor. Diabetes 55, 1484–1490.
37. Bäckhed F, Ding H, Wang T et al. (2004) The gut micro- biota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101, 15718–15723.
38. Erridge C, Attina T, Spickett CM et al. (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86, 1286–1292.
39. Vreugdenhil AC, Rousseau CH, Hartung T et al. (2003) Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 170, 1399– 1405.
40. Goldberg RF, Austen WG Jr, Zhang X et al. (2008) Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci USA 105, 3551–3556.
41. Cani PD, Amar J, Iglesias MA et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.
42. Geurts L, Neyrinck AM, Delzenne NM et al. (2014) Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular tar- gets and interventions using prebiotics. Benef Microbes 5, 3–17.
43. Khachatryan ZA, Ktsoyan ZA, Manukyan GP et al. (2008) Predominant role of host genetics in controlling the composition of gut microbiota. PLoS ONE 3, e3064.
44. Mariat D, Firmesse O, Levenez F et al. (2009) The firmi- cutes/bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 9, 123.
45. Mueller S, Saunier K, Hanisch C et al. (2006) Differences in fecal microbiota in different european study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 72, 1027–1033.
46. Louis P, Scott K, Duncan S et al. (2007) Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 102, 1197–1208.
47. Clarke SF, Murphy EF, O’Sullivan O et al. (2014) Exercise and associated dietary extremes impact on gut microbial diversity. Gut (Epublication ahead of print version).
48. Dethlefsen L, Huse S, Sogin ML et al. (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16 s rRNA sequencing. PLoS Biol 6, e280.
49. Liou AP, Paziuk M, Luevano J-M et al. (2013) Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5, 178ra141.
50. Jakobsson HE, Abrahamsson TR, Jenmalm MC et al. (2013) Decreased gut microbiota diversity, delayed bacter- oidetes colonisation and reduced th1 responses in infants delivered by caesarean section. Gut 80, 5116–5123.
51. Turnbaugh PJ, Ley RE, Mahowald MA et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1131.
52. Turnbaugh PJ, Hamady M, Yatsunenko T et al. (2009) A core gut microbiome in obese and lean twins. Nature 457, 480–484.
53. Ley RE, Bäckhed F, Turnbaugh P et al. (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102, 11070–11075.
54. Ley RE, Turnbaugh PJ, Klein S et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022.
55. Armougom F, Henry M, Vialettes B et al. (2009) Monitoring bacterial community of human gut microbiota reveals an increase in lactobacillus in obese patients and methanogens in anorexic patients. PLoS ONE 4(9): e7125.
56. Duncan S, Lobley G, Holtrop G et al. (2008) Human co- lonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond) 32, 1720–1724.
57. Schwiertz A, Taras D, Schafer K et al. (2010) Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18, 190–195.
58. Zhang H, DiBaise JK, Zuccolo A et al. (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 106, 2365–2370.
59. Kalliomäki M, Collado MC, Salminen S et al. (2008) Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 87, 534–538.
60. Santacruz A, Collado MdC, Garcia-Valdes L et al. (2010) Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in preg- nant women. Br J Nutr 104, 83–92.
61. Griffiths EA, Duffy LC, Schanbacher FL et al. (2004) In vivo effects of bifidobacteria and lactoferrin on gut endo- toxin concentration and mucosal immunity in balb/c mice. Dig Dis Sci 49, 579–589.
62. Wang Z, Xiao G, Yao Y et al. (2006) The role of bifidobac- teria in gut barrier function after thermal injury in rats. J Trauma 61, 650–657.
63. Neyrinck AM, Possemiers S, Verstraete W et al. (2012) Dietary modulation of clostridial cluster xiva gut bacteria (roseburia spp.) by chitin–glucan fiber improves host meta- bolic alterations induced by high-fat diet in mice. J Nutr Biochem 23, 51–59.
64. Neyrinck AM, Possemiers S, Druart C et al. (2011) Prebiotic effects of wheat arabinoxylan related to the in- crease in bifidobacteria, roseburia and bacteroides/prevo- tella in diet-induced obese mice. PLoS ONE 6, e20944.
65. Furet JP, Kong LC, Tap J et al. (2010) Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss links with metabolic and low- grade inflammation markers. Diabetes 59, 3049–3057.
66. Everard A, Lazarevic V, Derrien M et al. (2011) Responses of gut microbiota and glucose and lipid metabolism to pre- biotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775–2786.
67. Barcenilla A, Pryde SE, Martin JC et al. (2000) Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66, 1654– 1661.
68. Sokol H, Pigneur B, Watterlot L et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory com- mensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105, 16731–16736.
69. Derrien M, Vaughan EE, Plugge CM et al. (2004) Akkermansia muciniphila gen. Nov., sp. Nov., a human
Proceedings of the Nutrition Society
intestinal mucin-degrading bacterium. Int J Syst Evol
Microbiol 54, 1469–1476.
70. Derrien M, Van Baarlen P, Hooiveld G et al. (2011)
Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front Microbiol 2, 166.
71. Ridaura VK, Faith JJ, Rey FE et al. (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 6150.
72. Anastasovska J, Arora T, Sanchez Canon GJ et al. (2012) Fermentable carbohydrate alters hypothalamic neuronal activity and protects against the obesogenic environment. Obesity (Silver Spring) 20, 1016–1023.
73. Bomhof MR, Saha DC, Reid DT et al. (2014) Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats. Obesity (Silver Springs) 22, 763–771.
74. Dewulf EM, Cani PD, Claus SP et al. (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112–1121.
75. Parnell JA & Reimer RA (2009) Weight loss during oligo- fructose supplementation is associated with decreased ghre- lin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89, 1751–1759.
76. Genta S, Cabrera W, Habib N et al. (2009) Yacon syrup: beneficial effects on obesity and insulin resistance in humans. Clin Nutr 28, 182–187.
77. Guerin-Deremaux L, Li S, Pochat M et al. (2011) Effects of nutriose dietary fiber supplementation on body weight, body composition, energy intake, and hunger in overweight men. Int J Food Sci Nutr 62, 628–635.
78. IUB-IUPAC (1982) Abbreviated terminology of oligosac- charide chains. Eur J Biochem 126, 433–437.
79. Roberfroid M & Slavin J (2000) Nondigestible oligosac- charides. Crit Rev Food Sci Nutr 40, 461–480.
80. van Loo J, Coussement P, de Leenheer L et al. (1995) On the presence of inulin and oligofructose as natural ingredi- ents in the western diet. Crit Rev Food Sci Nutr 35, 525–552.
81. Tungland BC & Meyer D (2002) Nondigestible oligo- and polysaccharides (dietary fiber): their physiology and role in human health and food. Compr Rev Food Sci Food Safety 1, 90–109.
82. Blatchford P, Ansell J, de Godoy M et al. (2013) Prebiotic mechanisms, functions and applications – a review. Int J Probiotics Prebiotics 8, 109–132.
83. Gibson GR, Scott KP, Rastall RA et al. (2010) Dietary prebiotics: current status and new definition. Food Sci Technol Bull: Funct Foods 7, 1–19.
84. Woods MN & Gorbach SL (2001) Influences of fibre on the ecology of the intestinal flora. In CRC Handbook of Dietary Fibre in Human Nutrition, pp. 257–270 [G Spiller, editor]. Boca Raton, Florida: CRC Press.
85. Walton G, Swann J & Gibson G (2013) Prebiotics. In The Prokaryotes, pp. 25–43 [E Rosenberg, E DeLong, S Lory, E Stackebrandt and F Thompson, editors]. Berlin, Heidelberg: Springer.
86. Hobden MR, Martin-Morales A, Guerin-Deremaux L et al. (2013) In vitro fermentation of nutriose fb06, a wheat dextrin soluble fibre, in a continuous culture human colonic model system. PLoS ONE 8, e77128.
87. Grootaert C, Van den Abbeele P, Marzorati M et al. (2009) Comparison of prebiotic effects of arabinoxylan oligosac-
charides and inulin in a simulator of the human intestinal
microbial ecosystem. FEMS Microbiol Ecol 69, 231–242.
88. Hughes SA, Shewry PR, Li L et al. (2007) In vitro fermen- tation by human fecal microflora of wheat arabinoxylans. J
Agric Food Chem 55, 4589–4595.
89. Sanchez JI, Marzorati M, Grootaert C et al. (2009)
Arabinoxylan-oligosaccharides (AXOS) affect the protein/ carbohydrate fermentation balance and microbial popu- lation dynamics of the simulator of human intestinal mi- crobial ecosystem. Microb Biotechnol 2, 101–113.
90. Sarbini SR, Kolida S, Naeye T et al. (2011) In vitro fermen- tation of linear and alpha-1,2-branched dextrans by the human fecal microbiota. Appl Environ Microbiol 77, 5307–5315.
91. Timm DA, Stewart ML, Hospattankar A et al. (2010) Wheat dextrin, psyllium, and inulin produce distinct fer- mentation patterns, gas volumes, and short-chain fatty acid profiles in vitro. J Med Food 13, 961–966.
92. Pasman W, Wils D, Saniez MH et al. (2006) Long-term gastrointestinal tolerance of nutriose fb in healthy men. Eur J Clin Nutr 60, 1024–1034.
93. Dewulf EM, Cani PD, Neyrinck AM et al. (2011) Inulin-type fructans with prebiotic properties counteract gpr43 overexpression and PPARγ-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22, 712–722.
94. Kellow NJ, Coughlan MT & Reid CM (2014) Metabolic benefits of dietary prebiotics in human subjects: a system- atic review of randomised controlled trials. Br J Nutr 111, 1147–1161.
95. Daud NM, Ismail NA, Thomas EL et al. (2014) The im- pact of oligofructose on stimulation of gut hormones, appe- tite regulation and adiposity. Obesity (Silver Spring) 22, 1430–1438.
96. Nazare JA, Sauvinet V, Normand S et al. (2011) Impact of a resistant dextrin with a prolonged oxidation pattern on day-long ghrelin profile. J Am Coll Nutr 30, 63–72.
97. Cani PD, Lecourt E, Dewulf EM et al. (2009) Gut micro- biota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90, 1236–1243.
98. Overduin J, Schoterman MH, Calame W et al. (2013) Dietary galacto-oligosaccharides and calcium: effects on energy intake, fat-pad weight and satiety-related, gastroin- testinal hormones in rats. Br J Nutr 109, 1338–1348.
99. Cani PD, Joly E, Horsmans Y et al. (2005) Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 60, 567–572.
100. Verhoef SP, Meyer D & Westerterp KR (2011) Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide yy3–36 concentrations and energy intake. Br J Nutr 106, 1757–1762.
101. Hess JR, Birkett AM, Thomas W et al. (2011) Effects of short-chain fructooligosaccharides on satiety responses in healthy men and women. Appetite 56, 128–134.
102. Karalus M, Clark M, Greaves KA et al. (2012) Fermentable fibers do not affect satiety or food intake by women who do not practice restrained eating. J Acad Nutr Diet 112, 1356–1362.
103. Guerin-Deremaux L, Pochat M, Reifer C et al. (2011) The soluble fiber nutriose induces a dose-dependent beneficial impact on satiety over time in humans. Nutr Res 31, 665–672.
104. Kristensen M & Jensen MG (2011) Dietary fibres in the regulation of appetite and food intake. Importance of vis- cosity. Appetite 56, 65–70.
105. Salazar N, Dewulf EM, Neyrinck AM et al. (2014) Inulin-type fructans modulate intestinal bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr (Epublication ahead of print version).
106. Vulevic J, Juric A, Tzortzis G et al. (2013) A mixture of trans-galactooligosaccharides reduces markers of meta- bolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 143, 324–331.
107. Li S, Guerin-Deremaux L, Pochat M et al. (2010) Nutriose dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in
overweight men: a double-blind, randomized, placebo-
controlled study. Appl Physiol Nutr Metab 35, 773–782.
108. Paeschke T & Aimutis W (2010) Nondigestible
Carbohydrates and Digestive Health: Wiley-Blackwell.
109. Le-franc-Millot C, Wils D, Roturier JM et al. (2009) Nutriose soluble fiber. In Fiber Ingredients: Food Applications and Health Benefits, pp. 19–40 [S Cho and
P Samuel, editors]. Boca Raton, Florida: CRC Press.
110. Izydorczyk MS & Dexter JE (2008) Barley β-glucans and arabinoxylans: molecular structure, physicochemical properties, and uses in food products–a review. Food
Res Int 41, 850–868.
111. Swennen K, Courtin CM, Van der Bruggen B et al. (2005)
Ultrafiltration and ethanol precipitation for isolation of arabinoxylooligosaccharides with different structures. Carbohydr Polym 62, 283–292. University Staff: Request a correction | Centaur Editors: Update this record |
University of Reading
CentAUR: Central Archive at the University of Reading
Accessibility navigation
Potential anti-obesogenic properties of non-digestible carbohydrates: specific focus on resistant dextrin
Hobden, M. R., Guérin-Deremaux, L., Rowland, I., Gibson, G. R. Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1017/S0029665115000087 Abstract/SummaryAlterations in the composition and metabolic activity of the gut microbiota appear to contribute to the development of obesity and associated metabolic diseases. However, the extent of this relationship remains unknown. Modulating the gut microbiota with non-digestible carbohydrates (NDC) may exert anti-obesogenic effects through various metabolic pathways including changes to appetite regulation, glucose and lipid metabolism and inflammation. The NDC vary in physicochemical structure and this may govern their physical properties and fermentation by specific gut bacterial populations. Much research in this area has focused on established prebiotics, especially fructans (i.e. inulin and fructo-oligosaccharides); however, there is increasing interest in the metabolic effects of other NDC, such as resistant dextrin. Data presented in this review provide evidence from mechanistic and intervention studies that certain fermentable NDC, including resistant dextrin, are able to modulate the gut microbiota and may alter metabolic process associated with obesity, including appetite regulation, energy and lipid metabolism and inflammation. To confirm these effects and elucidate the responsible mechanisms, further well-controlled human intervention studies are required to investigate the impact of NDC on the composition and function of the gut microbiota and at the same time determine concomitant effects on host metabolism and physiology.
Altmetric Deposit Details References University Staff: Request a correction | Centaur Editors: Update this record |
Lists
Lists
